Evaluation of a blended-learning training concept to train oncology physicians to advise their patients about complementary and integrative medicine (KOKON-KTO): study protocol for a prospective, multi-center, cluster-randomized trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
29 Jan 2019
Historique:
received: 05 07 2018
accepted: 10 01 2019
entrez: 31 1 2019
pubmed: 31 1 2019
medline: 29 5 2019
Statut: epublish

Résumé

Many cancer patients are interested in complementary and integrative medicine during and after regular cancer treatment. Given the high number of users it is important that physicians and patients engage in a dialog about useful complementary and integrative medicine therapies during cancer treatment. In a prospective, multi-center, cluster-randomized evaluation study we will develop, implement and evaluate a training program for oncology physicians advising their patients on complementary and integrative medicine. The main objective of the study is to evaluate whether training physicians in a blended-learning approach (e-learning + skills-training workshop) in providing advice to their cancer patients on complementary and integrative medicine, in addition to handing out an information leaflet about reputable websites, has different effects on the outcomes of patients, physicians, and their interaction level, compared to only giving out the information leaflet. Forty-eight oncology physicians will be included into a cluster-randomized trial to either participate or not in the blended-learning training. Physicians will then advise 10 cancer patients each, resulting in 480 patients participating in the trial. The blended learning consists of nine units of up to 45 min of e-learning and 18 units of up to 45 min of on-site skills-training workshop focusing. Outcomes will be measured on the physician, patient, and physician-patient-interaction level. A blended-learning program for oncology physicians to advise their cancer patients in a systematic way and a reasonable time frame on complementary and integrative medicine will be evaluated in depth in a large cluster-randomized trial. German Clinical Trials Register, ID: DRKS00012704 . Registered on 28 August 2017.

Sections du résumé

BACKGROUND BACKGROUND
Many cancer patients are interested in complementary and integrative medicine during and after regular cancer treatment. Given the high number of users it is important that physicians and patients engage in a dialog about useful complementary and integrative medicine therapies during cancer treatment. In a prospective, multi-center, cluster-randomized evaluation study we will develop, implement and evaluate a training program for oncology physicians advising their patients on complementary and integrative medicine. The main objective of the study is to evaluate whether training physicians in a blended-learning approach (e-learning + skills-training workshop) in providing advice to their cancer patients on complementary and integrative medicine, in addition to handing out an information leaflet about reputable websites, has different effects on the outcomes of patients, physicians, and their interaction level, compared to only giving out the information leaflet.
METHODS/DESIGN METHODS
Forty-eight oncology physicians will be included into a cluster-randomized trial to either participate or not in the blended-learning training. Physicians will then advise 10 cancer patients each, resulting in 480 patients participating in the trial. The blended learning consists of nine units of up to 45 min of e-learning and 18 units of up to 45 min of on-site skills-training workshop focusing. Outcomes will be measured on the physician, patient, and physician-patient-interaction level.
DISCUSSION CONCLUSIONS
A blended-learning program for oncology physicians to advise their cancer patients in a systematic way and a reasonable time frame on complementary and integrative medicine will be evaluated in depth in a large cluster-randomized trial.
TRIAL REGISTRATION BACKGROUND
German Clinical Trials Register, ID: DRKS00012704 . Registered on 28 August 2017.

Identifiants

pubmed: 30696465
doi: 10.1186/s13063-019-3193-y
pii: 10.1186/s13063-019-3193-y
pmc: PMC6352447
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

90

Subventions

Organisme : German Cancer Aid
ID : 109863

Références

Arch Intern Med. 2002 May 27;162(10):1176-81
pubmed: 12020190
Complement Ther Med. 2004 Jun-Sep;12(2-3):90-8
pubmed: 15561518
Ann Oncol. 2005 Apr;16(4):655-63
pubmed: 15699021
Pharm World Sci. 2005 Apr;27(2):96-103
pubmed: 15999919
BMC Complement Altern Med. 2006 Dec 07;6:40
pubmed: 17156416
Ann Oncol. 2007 Mar;18(3):479-84
pubmed: 17272832
Psychother Psychosom Med Psychol. 2008 Jan;58(1):5-15
pubmed: 17429761
BMC Complement Altern Med. 2007 Aug 04;7:25
pubmed: 17683580
Health (London). 2008 Apr;12(2):139-55
pubmed: 18400826
Patient Educ Couns. 2010 Jan;78(1):130-3
pubmed: 19560303
Patient Educ Couns. 2010 May;79(2):143-51
pubmed: 19783116
Integr Cancer Ther. 2010 Jun;9(2):168-76
pubmed: 20462858
Integr Cancer Ther. 2012 Sep;11(3):187-203
pubmed: 22019489
Eur J Cancer. 2012 Nov;48(17):3133-9
pubmed: 22633625
J Altern Complement Med. 2014 Jan;20(1):12-8
pubmed: 23863085
Cancer Nurs. 2015 Mar-Apr;38(2):E10-26
pubmed: 25692736
Cancer Clin Oncol. 2013 Nov;2(2):81-92
pubmed: 26640610
Support Care Cancer. 2016 Sep;24(9):3857-62
pubmed: 27075675
Patient Educ Couns. 2016 Nov;99(11):1858-1864
pubmed: 27345253
Integr Cancer Ther. 2018 Jun;17(2):380-387
pubmed: 27585628
BMC Cancer. 2016 Nov 4;16(1):843
pubmed: 27809814
PLoS One. 2016 Nov 3;11(11):e0165801
pubmed: 27812163
Support Care Cancer. 2017 May;25(5):1485-1494
pubmed: 28025709
Complement Ther Med. 2017 Aug;33:78-84
pubmed: 28735830

Auteurs

Stefanie M Helmer (SM)

Institute for Social Medicine, Epidemiology, and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Alizé A Rogge (AA)

Institute for Social Medicine, Epidemiology, and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Felix Fischer (F)

Department of Psychosomatic Medicine, Center for Internal Medicine and Dermatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Daniel Pach (D)

Institute for Social Medicine, Epidemiology, and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Markus Horneber (M)

Department of Internal Medicine, Division of Oncology and Hematology, Paracelsus Medical University, Klinikum Nuremberg, Nuremberg, Germany.

Stephanie Roll (S)

Institute for Social Medicine, Epidemiology, and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Claudia M Witt (CM)

Institute for Social Medicine, Epidemiology, and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. claudia.witt@charite.de.
Institute for Complementary and Integrative Medicine, University of Zurich and UniversityHospital Zurich, Zurich, Switzerland. claudia.witt@charite.de.
Center for Integrative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. claudia.witt@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH